Herantis Pharma

1,65

EUR

−0,6 %

Företagskund

HRTIS

First North Finland

Bioteknik & Läkemedel

Hälsovård

4 214 investerare följer bolaget.

Jämför

−0,6%

+30,95%

+10,37%

−0,3%

+4,76%

+3,77%

−25,22%

−78,18%

−83,62%

Herantis Pharma är ett bioteknikbolag i klinisk fas som utvecklar sjukdomsmodifierande terapier för Parkinsons sjukdom. Bolagets ledande produkt HER-096 är en liten syntetisk kemisk peptidomimetisk molekyl utvecklad baserat på CDNF-proteinets aktiva plats. HER-096 kombinerar verkningsmekanismen för CDNF med subkutan administrering. Herantis Pharma grundades 2008 och har sitt huvudkontor i Esbo, Finland.

Läs mera

Börsvärde

33,27 mn EUR

Omsatt (värde)

25,06 tn EUR

P/E (just.) (24e)

EV/EBIT (adj.) (24e)

P/B (24e)

EV/S (24e)

Direktavkastnings- % (24e)

Coverage

Rekommendation

Öka

Riktkurs

Uppdaterad

23.08.2024

Disclaimer

Latest research

Latest analysis report

Released: 23.08.2024

Latest extensive report

Released: 25.06.2024

Finansiell kalender

6.3.

2025

Årsredovisning '24

24.4.

2025

Bolagsstämma '24

21.8.

2025

Delårsrapport Q2'25

Risk

Business risk

Valuation risk

Låg

Hög

VisarAlla typer av innehåll

Drug development investment: Value creation through M&As and licensing agreements

Artikel2024-12-19 11:07 av

Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Regulatoriskt pressmeddelande2024-12-12 14:00

Herantis Pharma’s financial calendar and annual general meeting for 2025

Herantis Pharma

Regulatoriskt pressmeddelande2024-12-10 16:30

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2025

Herantis Pharma

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

FREE account

Stock market's most popular morning newsletter

Tillgång till analytikerkommentarer och rekommendationer

Vårt eget aktiescreeningsverktyg

PREMIUM account

Alla aktieanalyser och övrigt innehåll

Premiumverktyg (insidertransaktioner och aktiescreeningsverktyg)

Inderes modellportfölj

Skapa användarkonto

Video2024-12-03 12:50

Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024

Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

Herantis Pharma

Analytikerkommentar2024-12-03 06:52

Life Science Night available on inderesTV

Aiforia Technologies Herantis Pharma Faron Pharmaceuticals

Video2024-12-02 14:00

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Webcast2024-12-02 14:00

Life Science Night | December 2, 2024

Welcome to follow Life Science Night on Monday, December 2 at 4:00 pm EET on inderesTV.

Aiforia Technologies Herantis Pharma Faron Pharmaceuticals

Analytikerkommentar2024-12-03 10:21 av

Antti Siltanen

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Analytikerkommentar2024-11-12 06:53 av

Antti Siltanen

Part 1 of the Herantis trial completed

Herantis issued a press release on Monday announcing the completion of the Part 1 of the Phase Ib clinical trial of the drug candidate HER-096 in healthy volunteers.

Herantis Pharma

Pressmeddelande2024-11-11 15:05

Herantis Pharma has successfully completed the Part 1 of the Phase 1b clinical trial

Herantis Pharma

Pressmeddelande2024-11-04 10:00

Herantis Pharma Oyj: Herantis Pharma will present at the BioStock Life Science Summit, November 20

Herantis Pharma

Pressmeddelande2024-11-04 10:00

Herantis Pharma Oyj: Herantis Pharma presenterar på BioStock Life Science Summit 20 november

Herantis Pharma

Analytikerkommentar2024-10-24 05:48 av

Antti Siltanen

Herantis R&D webinar complemented scientific background and roadmap

Herantis organized a webinar on Wednesday to discuss the base research, clinical trial program and financial status of HER-096.

Herantis Pharma

Pressmeddelande2024-10-23 05:30

Herantis Pharma: Key messages from today’s R&D webinar

Herantis Pharma

Analytikerkommentar2024-10-17 05:28 av

Antti Siltanen

Herantis clinical trial started as planned

Herantis issued a press release on Wednesday stating that HER-096 dosing has started in the Phase Ib trial.

Herantis Pharma

Pressmeddelande2024-10-16 07:30

Herantis Pharma: HER-096 dosing started in the Phase 1b trial

Herantis Pharma

Pressmeddelande2024-10-08 05:00

Herantis Pharma to host R&D webinar on October 23, 2024

Herantis Pharma

Regulatoriskt pressmeddelande2024-10-02 10:15

Composition of Herantis Pharma Plc's Shareholders' Nomination Committee

Herantis Pharma

Probabilities of success in drug development

Artikel2024-09-26 13:26 av

Antti Siltanen

Probabilities of success in drug development

The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development.

Faron Pharmaceuticals Herantis Pharma Mendus

Analytikerkommentar2024-09-20 06:10 av

Antti Siltanen